Executive-in-Residence Scott Fisher Named CEO of CavoGene LifeSciences
February 11, 2019
Fisher has previously led drug development and gene therapy clinical research of multiple regenerative therapies at early-stage companies, according to the news release.
CavoGene, which will be headquartered at the Global Center for Health Innovation in Cleveland, has secured the exclusive license to SynCav1, a novel and neuron specific gene therapy, from the University California San Diego and the laboratory of Brian P. Head.